Growing emphasis on patient safety and regulatory compliance is fueling the expansion of the Blood Transfusion Diagnostics Market. Modern diagnostic systems enable faster and more precise blood screening, ensuring high-quality transfusion practices. With rising healthcare expenditures and technological progress, the market is witnessing increased adoption across hospitals, blood banks, and diagnostic laboratories. 

According to The Insight Partners, the Blood Transfusion Diagnostics Market is expected to grow from US$ 4,096.93 million in 2021 to US$ 6,483.75 million by 2028. The market is estimated to expand at a compound annual growth rate of 6.9 percent from 2022 to 2028. The market outlook highlights the growing significance of diagnostic instruments, kits, and reagents in ensuring blood safety and supporting the detection of diseases and infections before transfusion.

Download the Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00005176

Blood Transfusion Diagnostics Market Size and Forecast

The blood transfusion diagnostics market is projected to demonstrate sustained expansion through 2028. Its growth from US$ 4,096.93 million in 2021 to US$ 6,483.75 million by 2028 reflects the increasing importance of diagnostic testing in blood banks, hospitals, and diagnostic laboratories. The estimated compound annual growth rate of 6.9 percent between 2022 and 2028 indicates continued opportunities for companies operating in the blood transfusion diagnostics industry.

Blood transfusion diagnostics include tests performed on donated blood and blood components before they are transfused into patients. Blood typing and disease screening are essential procedures for identifying compatible blood and reducing the risk of infection transmission and transfusion-related complications. These requirements make diagnostic products an important part of blood management and healthcare delivery.

Key Market Drivers

The growing need for blood transfusions due to increasing organ transplant surgeries is one of the major drivers of market expansion. Transplant procedures involving organs such as the heart, liver, and kidneys can involve substantial blood loss, creating demand for blood transfusion services and the diagnostic tests required to support them.

The increasing prevalence of chronic diseases and the growing number of surgical procedures also contribute to market demand. As healthcare providers manage complex medical conditions, blood typing and disease screening remain essential for safe transfusion practices.

Technological advancements and the introduction of advanced molecular platforms are additional factors supporting market development. In Asia Pacific, improvements in blood transfusion management, the prevalence of conditions such as sepsis and thalassemia, and the adoption of advanced diagnostic approaches are contributing to regional growth.

Blood Transfusion Diagnostics Market Segmentation

The market is segmented by product, application, and end user, providing several opportunities for industry participants.

By Product: The market comprises instruments and kits, and reagents. Instruments and kits accounted for the largest market share in 2021, representing 66.7 percent of the market. This segment is also expected to register a higher compound annual growth rate during the forecast period.

By Application: The market is divided into disease screening and blood grouping. Disease screening held a leading market position in 2021 and is anticipated to experience the fastest growth, with an estimated compound annual growth rate of 7.1 percent during the forecast period.

By End User: The market includes blood banks, hospitals, diagnostic laboratories, and plasma fractionation companies. Blood banks accounted for the largest share in 2021, at approximately 40.2 percent, and are expected to register the highest compound annual growth rate through 2028.

These segments demonstrate the importance of diagnostic testing across blood collection, screening, and transfusion-related healthcare services.

Regional Market Growth and Opportunities

North America held 41.8 percent of the global blood transfusion diagnostics market in 2021, establishing its position as the leading regional market. Growth in the region is supported by surgical procedures for chronic health conditions, collaboration among key industry participants, and developments in blood transfusion diagnostic services. The United States market is projected to grow at a compound annual growth rate of 7.4 percent during the forecast period.

Asia Pacific represents a significant growth opportunity, with an estimated compound annual growth rate of 7.9 percent. Improvements in blood transfusion management and the introduction of advanced molecular platforms are contributing to the region's expansion.

Europe, the Middle East and Africa, and South and Central America also form important parts of the global market. The geographic coverage of the market creates opportunities for companies to expand their diagnostic product portfolios and strengthen their presence across different healthcare systems.

Top Key Players in the Blood Transfusion Diagnostics Market

The competitive landscape includes established healthcare and diagnostic companies focusing on product launches, portfolio expansion, and market development. The key players identified by The Insight Partners include:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Grifols, S.A.
• DiaSorin S.p.A.
• Ortho Clinical Diagnostics
• BAG Diagnostics GmbH
• Immucor, Inc.
• Quotient Limited

These companies operate in a market where diagnostic product development and portfolio expansion are important strategies for meeting demand. Competition among established participants also shapes the development of innovative products and services.

Market Growth and Future Opportunities

The forecast growth of the blood transfusion diagnostics market creates opportunities in instruments and kits, disease screening, and blood bank testing. Companies can focus on diagnostic solutions that support reliable blood typing and the identification of infections before transfusion. Expanding demand associated with organ transplantation and chronic diseases further reinforces the need for effective diagnostic procedures.

Disease screening is particularly significant because it is expected to record the fastest growth among application segments. Similarly, blood banks represent an important end-user opportunity due to their leading market share and projected growth.

Future Outlook

The global blood transfusion diagnostics market is expected to maintain its growth trajectory through 2028, reaching US$ 6,483.75 million at a compound annual growth rate of 6.9 percent from 2022 to 2028. Increasing demand for blood transfusions, the need for disease screening, and developments in diagnostic technologies are expected to remain important market influences. With North America maintaining a leading position and Asia Pacific emerging as a high-growth region, companies have opportunities to strengthen their product offerings and regional presence. Continued developments in diagnostic instruments, kits, and reagents will remain important to the market's future direction.

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

Contact Us:
Contact Person: Ankit Mathur 
E-mail: [email protected]
Phone: +1-646-491-9876